The 10-second takeaway
For the quarter ended June 30 (Q1), PetMed Express beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew. GAAP earnings per share increased significantly.
Margins increased across the board.
PetMed Express reported revenue of $74.2 million. The seven analysts polled by S&P Capital IQ expected net sales of $70.0 million on the same basis. GAAP reported sales were 7.6% higher than the prior-year quarter's $69.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.24. The seven earnings estimates compiled by S&P Capital IQ forecast $0.22 per share. GAAP EPS of $0.24 for Q1 were 20% higher than the prior-year quarter's $0.20 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 32.4%, 10 basis points better than the prior-year quarter. Operating margin was 10.1%, 110 basis points better than the prior-year quarter. Net margin was 6.4%, 70 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $59.0 million. On the bottom line, the average EPS estimate is $0.21.
Next year's average estimate for revenue is $233.3 million. The average EPS estimate is $0.88.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 870 members out of 900 rating the stock outperform, and 30 members rating it underperform. Among 243 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 238 give PetMed Express a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is hold, with an average price target of $12.70.
Is PetMed Express the right Internet stock for your portfolio? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average retailing powerhouse. Click here for instant access to this free report.
- Add PetMed Express to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.